Annual report
2934.TEDINET S100P44C
Period2021-06-01 → 2022-05-31
Filed2022-08-31
StandardJapan GAAP
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 98
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | ¥732m | 2021-06-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | ¥713m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥702m | 2021-06-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥400m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31 | Cons. | Net assets |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 68.2% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 278 | at 2022-05-31 | Cons. | Number of employees |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31 | Standalone | Net sales |
| Revenue | ¥7.1bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2017-06-01 → 2018-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥751m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Operating income | ¥672m | 2020-06-01 → 2021-05-31 | Standalone | Operating income |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥174m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥367m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥589m | 2017-06-01 → 2018-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥723m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥679m | 2020-06-01 → 2021-05-31 | Standalone | Income before income taxes |
| Net income | ¥450m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥425m | 2020-06-01 → 2021-05-31 | Standalone | Profit loss |
| Net income | ¥96m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥399m | 2017-06-01 → 2018-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.3bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥2.6bn | at 2021-05-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.5bn | at 2018-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.1bn | at 2022-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.3bn | at 2021-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31 | Standalone | Net assets |
| Net assets / equity | ¥843m | at 2020-05-31d | Standalone | Net assets |
| Net assets / equity | ¥746m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥739m | at 2018-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.4bn | at 2022-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2021-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥902m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥948m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥218m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥63m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥99m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥130m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.12 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.6 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.98 | 2017-06-01 → 2018-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.25 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥194.13 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥385.07 | at 2018-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.0% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2018-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 74.0% | 2017-06-01 → 2018-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2018-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 54 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31 | Standalone | Number of employees |
| Employees | 47 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 42 | at 2019-05-31d | Standalone | Number of employees |
| Employees | 37 | at 2018-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥2.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-05-31 | −¥425m |
| Healthcare Marketing Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥362m |
| Healthcare Marketing Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥2m |
| Healthcare Marketing Businessreportable segment | employees | at 2022-05-31 | 99 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.9bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.8bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2022-05-31 | ¥1.3bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥37m |
| Healthcare Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥703,000 |
| Healthcare Sales Businessreportable segment | employees | at 2022-05-31 | 23 pure |
| Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥251m |
| Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥779m |
| Medical Care Sales Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥544m |
| Medical Care Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥3m |
| Medical Care Sales Businessreportable segment | employees | at 2022-05-31 | 142 pure |
| Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥1.8bn |
| Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥340m |
| —segment total | employees | at 2022-05-31 | 278 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥907m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.2bn |
| Healthcare Marketing Businessreportable segment | employees | at 2022-05-31 | 10 pure |
| Healthcare Sales Businessreportable segment | employees | at 2022-05-31 | 23 pure |
| Medical Care Sales Businessreportable segment | employees | at 2022-05-31 | 10 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,094
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 37.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 2.8 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6035000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 10 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 7 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 23 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 10 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 11 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 54 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Research and development expenses research and development activities | CurrentYearDuration | 8230000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 6866000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 1363000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4757616 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4759320 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4757616 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4759320 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 3 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 17 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 8 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 2064 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 2149 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 779 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 846 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 10701 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 565 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 22 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 34639 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 47552 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 2416 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | 0.00 | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0164 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0178 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2250 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0119 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0005 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.7284 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 2417000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.5303 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1000000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.2194 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 17 of 17 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |